Looking Past Aduhelm, Biogen Puts Pipeline On Display
Data Expected From Six Trials For Five Drugs Through 2022
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
You may also be interested in...
Priya Singhal took over as Biogen's top R&D leader on an interim basis after Al Sandrock’s unexpected retirement. "I understand that this is a challenging time," she told Scrip.
Following Biogen’s lead with Aduhelm, the first disease-modifying Alzheimer’s therapy approved in the US, Eisai began a rolling BLA submission for lecanemab (BAN2401) ahead of next year’s Phase III results.
In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.